目的：分析肝硬化患者和健康人的黄斑区视网膜厚度、视网膜体积和脉络膜厚度的差异，初步探讨肝硬化患者视网膜和脉络膜的改变。

方法：采用横断面观察研究。将2015-01/2018-03我院肝硬化患者84例168眼和健康人50例100眼(正常对照组)纳入研究，其中肝硬化患者包括肝硬化代偿期组34例68眼，肝硬化失代偿期组50例100眼。采用OCT对所有受检眼测量黄斑区视网膜厚度和体积。采用EDI-OCT行脉络膜厚度扫描，以Bruch膜强反射线到脉络膜巩膜交界面强反射线的垂直距离作为脉络膜厚度。分析三组受检眼黄斑区视网膜厚度、视网膜体积和脉络膜厚度的差异。

结果：三组受检者黄斑区各象限视网膜厚度和视网膜体积无差异(P>0.05)。三组中心凹下脉络膜厚度分别为338.50±70.44、357.00±89.16、319.53±74.37μm(P>0.05)。三组间中心凹鼻侧脉络膜厚度有差异(P<0.05)； 肝硬化失代偿组与正常对照组比较，鼻侧脉络膜偏厚(P<0.05)。

结论：肝硬化失代偿期患者较健康者中心凹鼻侧脉络膜偏厚，肝硬化患者与健康人黄斑区视网膜厚度、视网膜体积无明显差异。

METHODS: A cross-sectional study. From January 2015 to March 2018, 168 eyes of 84 patients with liver cirrhosis and 100 eyes of 50 healthy people were included. Healthy people were the normal control group. The patients were divided into two groups, including compensated cirrhosis group(68 eyes of 34 patients)and decompensated cirrhosis group(100 eyes of 50 patients). All eyes underwent OCT examination to measure the retinal thickness and retinal volume in the macular area. EDI-OCT was used for choroidal thickness scanning, and the vertical distance between the strong reflection of Bruch film and the strong reflection of the choroidal sclera interface was defined as the choroidal thickness. The retinal thickness, retinal volume and choroidal thickness in the macular area in the three groups were compared and analyzed.

RESULTS: The differences in retinal thickness and retinal volume between three groups were not significant(P>0.05). The subfoveal choridal thickness(SFCT)of three groups were 338.50±70.44, 357.00±89.16, 319.53±74.37μm(P>0.05). There was a statistically significant difference in nasal choroid thickness between the three groups(P<0.05). The choridal thickness in nasal area to fovea in the patients with decompensated cirrhosis was increased than that in healthy people(P<0.05).

CONCLUSION: The choridal thickness in nasal area to fovea in the patients with decompensated cirrhosis is thicker than that in healthy people. There are no significant differences in retinal thickness or retinal volume in macular area between healthy people and patients with liver cirrhosis.